An interventional study of concentrated beetroot juice (400mg of nitrate per serving) and concentrated beetroot juice (trace amounts of nitrate per serving) in Interstitial Lung Disease, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by University of British Columbia · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Lung Diseases, Interstitial with a site in Canada — 21 open to participants now, 28 under way, 9 of them phase 3. Lung Diseases, Interstitial · Canada.
Among the 64 studies in Lung Diseases, Interstitial with a site in Canada, this one is the 52nd largest by planned enrollment of the 57 interventional ones that give a count, is one of 10 that started in 2024, is one of 18 with no phase, reaches primary completion later than 6 of the 27 other live ones, and was the 26th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →21 of the 64 studies in Lung Diseases, Interstitial with a site in Canada are open now. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 17 more countries
Ages 18+
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 19 more countries
Ages 2–17
Liquidia Technologies, Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 18–80
Boehringer Ingelheim · Sites in Canada, United States, Argentina and 10 more countries
Ages 40+
Contineum Therapeutics · Sites in Canada, Argentina, Australia and 16 more countries
Ages 40+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 20 · Phase 3 19
First in 2003; this study’s year is marked. 10 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 80 across the 57 interventional studies, 79 across the 7 observational. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 64 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 3 studies filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
10 of the studies in Lung Diseases, Interstitial with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT05785065Centre hospitalier de l'Université de Montréal (CHUM)Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease | 2026-12 |
| NCT04299945University of British ColumbiaEffects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease | 2026-12-31 |
| NCT03800017University of British ColumbiaSkeletal Muscle Function in Interstitial Lung Disease | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 64 studies in Lung Diseases, Interstitial with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.
PURPOSE:
The primary purpose of this study is to determine the effects of dietary nitrate supplementation on submaximal cycle exercise performance in patients with fibrotic ILD.
HYPOTHESIS:
Our primary hypothesis is that dietary nitrate supplementation will result in greater improvement in submaximal cycle exercise endurance time compared with placebo.
JUSTIFICATION:
Fibrotic interstitial lung disease (ILD) is a heterogeneous group of disorders that cause scarring/fibrosis or inflammation of the lungs, resulting in significant morbidity and high mortality. Almost all ILDs are characterized by dyspnoea and functional limitation and there are few effective and/or well-tolerated pharmacotherapies for many ILD subtypes.
Exertional dyspnoea leads to reduced exercise capacity in ILD, and this functional limitation is further worsened by skeletal muscle weakness and dysfunction. Both dyspnoea and poor exercise tolerance are strongly associated with quality of life and mortality in ILD and thus improving dyspnoea and functional capacity are important goals in the management of ILD.
Pulmonary rehabilitation is a structured evidence-based exercise and education intervention that is recommended for most patients with ILD. Pulmonary rehabilitation improves dyspnoea, functional capacity, and quality of life in patients with ILD; however, these benefits are often modest and only temporary. The exercise component of pulmonary rehabilitation is the predominant mediator of benefit; however, there are no studies that have investigated the optimal method of exercise training in patients with ILD. Thus, there is a clear need to identify new strategies that can provide larger and more persistent benefits from pulmonary rehabilitation.
Nitric oxide (NO) is a physiological signaling molecule that plays a critical role in vascular control. There is accumulating evidence that dietary nitrate, consumed in the form of beetroot juice, can increase the bioavailability of NO and subsequently enhance exercise performance in healthy, elite athlete, as well as diseased populations. These improvements may be related, but not limited to, enhanced efficiency of locomotion, peripheral locomotor oxygen delivery, and/or muscle power. The specific effects of dietary nitrate supplementation in ILD patients has yet to be explored. However, there is great potential for the use of this dietary supplement to improve exercise tolerance during, and improve patient outcomes from, pulmonary rehabilitation.
STATISTICAL ANALYSIS:
A p value \<0.05 will be considered significant for all analyses. Data analysis will be performed using Microsoft Excel 2013 (Microsoft Corporation, Redmond, Washington, US) and Stata v12 (StataCorp, Texas, US).
Primary outcome: The primary outcome of cycle endurance time will be based on the duration patients were able to exercise during the constant work rate exercise test. A t-test will be used to compare endurance times between the intervention and placebo conditions.
The investigators have chosen to power this study based on the primary outcome of change in cycle exercise endurance time. Based on previously collected data in our laboratory in patients with ILD that show a standard deviation of 289.96 seconds for a 75% constant work rate cycle exercise test with a conservative between test correlation of 0.90, the investigators calculated that 15 participants would be needed to detect the minimal clinically important difference of 105 seconds between conditions assuming a two-sided α of 0.05 and 80% power.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The dietary nitrate supplement will be a concentrated, nitrate-rich beetroot juice (70 ml providing ∼400mg nitrate per serving)
Dietary Supplement: concentrated beetroot juice (400mg of nitrate per serving)
The placebo will be a concentrated, nitrate-depleted beetroot juice (70 ml with trace amounts of nitrate)
Dietary Supplement: concentrated beetroot juice (trace amounts of nitrate per serving)
Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
Difference in submaximal cycle exercise endurance time following dietary nitrate supplementation compared to placebo supplementation.
Exercise endurance time will be measured during submaximal constant load cycle exercise testing.
Time frame: 1 Week
Difference in exertional dyspnoea during submaximal cycle exercise following dietary nitrate supplementation compared to placebo supplementation.
Dyspnea rating, measured using the Borg 0-10 category ratio scale, will be assessed at rest and every 1 minute during submaximal constant load cycle exercise testing until exhaustion.
Time frame: 1 Week
Difference in exertional dyspnoea during activities of daily living following dietary nitrate supplementation compared to placebo supplementation.
Shortness of breath during daily living patterns will be assessed using established questionnaires.
Time frame: 1 Week
Difference in concentration of plasma nitrate ([NO3-]) and nitrite ([NO2-]) following dietary nitrate supplementation compared to placebo supplementation.
Blood samples will be taken and analyzed for the concentration levels of nitrates in blood plasma.
Time frame: 1 Week
Difference in resting, exercise, and post-exercise blood pressure following dietary nitrate supplementation compared to placebo supplementation.
Blood pressure will be measured using a manual sphygmomanometer at rest, every 2 minutes during submaximal constant load cycle exercise testing until exhaustion, and 5 minutes after exercise ends.
Time frame: 1 Week
Difference in oxygen cost of submaximal cycle exercise following dietary nitrate supplementation compared to placebo supplementation.
Oxygen consumption will be measured during submaximal constant load cycle exercise testing.
Time frame: 1 Week
Difference in peripheral locomotor muscle oxygenation following dietary nitrate supplementation compared to placebo supplementation.
Peripheral locomotor muscle oxygenation will be monitored using near-infrared spectroscopy during submaximal constant load exercise testing.
Time frame: 1 Week
Difference in post-exercise quadriceps fatigue following dietary nitrate supplementation compared to placebo supplementation.
Quadriceps fatigue will be assessed by measuring the quadriceps muscle force output using the femoral magnetic stimulation technique immediately before and after submaximal constant load exercise testing.
Time frame: 1 Week
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 114 non-industry interventional studies with no phase under Lung Diseases, Interstitial, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 28 months is close to that.
Counting every sponsor, half of 119 studies reached it within 27 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →